63% of employers say PBMs not transparent about how they make money
Published by Becker’s Hospital Review
Many U.S. employers are concerned about their pharmacy benefit manufacturer’s level of transparency, contract complexity and rebate process, according to a report conducted by Benfield on behalf of the National Pharmaceutical Council.
Researchers interviewed eight industry experts, including employers, PBMs and pharmacists. Researchers also surveyed health benefit leaders from 88 large U.S. employers in the first quarter of 2017 and later conducted follow-up interviews with eight of the survey participants.
Here are four survey findings to know.
1. Only 30 percent of respondents said they understand the details of their PBM contracts, and 40 percent said they understand their PBM’s performance guarantees.
2. Sixty-three percent of respondents felt PBMs are not transparent about how they make money.
3. Fifty-eight percent of respondents thought contracts are too complicated and ambiguous, often benefiting the PBM at the employer’s expense.
4. Most employers (69 percent) said they want to see PBMs implement an alternative to rebates, such as discounts or point-of-sale rebates, reflected in the patient payment.
Click here to see the original article on the Becker’s Hospital Review website.
Recent Posts
-
Senior Care Pharmacy Coalition Shares Comments with CMS Regarding Medicare Part D Restructuring Guidance: “Smoothing Provisions”
SCPC filed comments with CMS in response to their guidance on the implementation of the Medicare Part D restructuring portion of the Inflation Reduction Act (IRA).
-
Drug pricing efforts threaten ‘very existence’ of LTC pharmacies: reps
President Biden in his State of the Union address last week vowed to end “Big Pharma’s” grip on prescription drug pricing and cut costs for seniors and taxpayers by another $200 million.
But the president’s plans to expand his administration’s first-ever Medicare drug price negotiations could spell big trouble for the pharmacists who support seniors living in long-term care settings, advocates warned in response. -
President Biden Announces Desire to Cap Drug Prices for All Americans
In the State of the Union Address on March 7th, President Joseph Biden announced a proposal to expand the number of drugs targeted for annual price negotiations by Medicare and lower prescription drug costs for American families.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.